Dr. Reddy's Laboratories Limited

DRREDDY

INE089A01023

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:53 2024-07-16 am EDT			5-day change	1st Jan Change
6,643 ^INR	-2.20%		+0.91%	+14.58%

04:47pm	Asian Equities Traded in the US as American Depositary Receipts Tumble in Wednesday Trading	MT
Jul. 16	Asian Equities Traded in the US as American Depositary Receipts Move Modestly Higher in Tuesday Trading	MT

Dr. Reddy’s Laboratories Ltd acquired Trademark rights of the breast cancer drug PRIMCYV from Pfizer Products India Pvt Ltd.

January 12, 2023

Dr. Reddy's Laboratories Ltd acquired Trademark rights of the breast cancer drug PRIMCYV from Pfizer Products India Pvt Ltd on January 13, 2023.

Dr. Reddy's Laboratories Ltd Completed the acquisition of Trademark rights of the breast cancer drug PRIMCYV from Pfizer Products India Pvt Ltd on January 13, 2023.

Latest news about Dr. Reddy's Laboratories Limited

Asian Equities Traded in the US as American Depositary Receipts Tumble in Wednesday Trading	10:47am	MT
Asian Equities Traded in the US as American Depositary Receipts Move Modestly Higher in Tuesday Trading	Jul. 16	MT
Indian Equities Achieve New Closing Highs on Tuesday, Led by Realty, FMCG Goods Stocks	Jul. 16	MT
Jefferies Forecasts Strong Fiscal Q1 for Indian Pharmaceuticals	Jul. 16	MT
Asian Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Trading	Jul. 15	MT
Dr. Reddy's Laboratories Limited Receives an Order from The Joint Commissioner,, Office of the Commissioner of Central Tax, Kochi Towards Tax Demand Including Interest and Penalty	Jul. 15	CI
Asian Equities Traded in the US as American Depositary Receipts Climb Higher in Wednesday Trading	Jul. 10	MT
Asian Equities Traded in the US as American Depositary Receipts Open Week Slightly Higher in Monday Trading	Jul. 08	MT
Asian Equities Traded in the US as American Depositary Receipts Decline in Friday Trading	Jul. 05	MT
Asian Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	Jul. 03	MT
Asian Equities Traded in the US as American Depositary Receipts Open Week on Flat Note	Jul. 01	MT
Dr. Reddy's to Co-market Zydus' Breast Cancer Treatment in India	Jun. 28	MT
Zydus and Dr. Reddy's Announces Licensing Agreement for Co-Marketing of Pertuzumab Biosimilar, a Critical Treatment for Breast Cancer Patients in India	Jun. 28	CI
India plans incentives for diabetes, obesity drug makers in 2026, government official says	Jun. 28	RE
Indian Equities Fall on Friday, Dragged Mainly by Banking Stocks	Jun. 28	MT
Asian Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	Jun. 27	MT
Dr. Reddy's to Acquire Haleon's Nicotine Replacement Therapy Business Outside US	Jun. 27	MT
INDIA STOCKS-UltraTech Cement, Reliance power Indian shares to record highs	Jun. 27	RE
Dr. Reddy's Laboratories to Acquire Nicotinell Portfolio From Haleon	Jun. 26	MT
Haleon to Sell Nicotine-Quitting Aid Business for $634 Million -- Update	Jun. 26	DJ
Transcript : Dr. Reddy's Laboratories Limited - Special Call	Jun. 26
Haleon to Sell Nicotine-Quitting Aid Business for $634 Million	Jun. 26	DJ
Haleon to sell nicotine replacement therapy business outside US for $633 mln	Jun. 26	RE
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Tuesday Trading	Jun. 25	MT
Asian Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	Jun. 24	MT

Chart Dr. Reddy's Laboratories Limited

Duration

Period

More charts

Company Profile

Dr. Reddy's Laboratories specializes in developing, producing, and selling pharmaceutical products. Net sales break down by activity as follows: - sales of generic medications (79.9%): brand-name or generic prescription medications and OTC medicines; - sales of active ingredients (15.7%). The group also supplies customized pharmaceutical services; - other (4.4%): sales of generic biopharmaceutical products, development of molecular agents, etc. Net sales are distributed geographically as follows: India (18.8%), the United States (45%), Russia (9.9%) and other (26.3%).

Sector

Pharmaceuticals

Calendar

2024-07-26 - Q1 2025 Earnings Release

Related indices

NIFTY 50 , NIFTY 100

More about the company

Income Statement Evolution

More financial data

Ratings for Dr. Reddy's Laboratories Limited

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

6,643 INR

Average target price

6,164 INR

Spread / Average Target

-7.21%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
DR. REDDY'S LABORATORIES LIMITED	+14.58%	13.24B
ELI LILLY AND COMPANY	+57.21%	848B
NOVO NORDISK A/S	+31.64%	627B
JOHNSON & JOHNSON	-0.55%	363B
MERCK & CO., INC.	+15.35%	318B
ABBVIE INC.	+12.35%	299B
ASTRAZENECA PLC	+15.51%	243B
NOVARTIS AG	+16.72%	225B
AMGEN INC.	+16.20%	179B
PFIZER, INC.	+3.23%	167B

Other Pharmaceuticals

Dr. Reddy's Laboratories Limited

Equities

DRREDDY

INE089A01023

Pharmaceuticals

Dr. Reddy’s Laboratories Ltd acquired Trademark rights of the breast cancer drug PRIMCYV from Pfizer Products India Pvt Ltd.

EPS Revisions